In clinical trials of patients with various types of retinal diseases, including macular degeneration, diabetic retinopathy, retinitis pigmentosa, and hemorrhagic and hypertensive retinopathy, all persons given Flavay® showed significant improvement.

A Completely Safe, Non-Drug, Natural Approach to Normalizing Eye Function and Vision

Licensed and sold for eye health in France, the vascular protective activity of Flavay® has been established by many significant studies.

Flavay® has been sold world-wide for vascular and eye health and extensively tested in humans for more than 60 years. The vascular protective activity of Flavay® has been established by many significant studies, demonstrating several important ways in which Flavay® may protect the vascular health of the eyes. Flavay® can protect the eyes from free radical damage, support overall circulatory function, reinforce collagen structures of the retina, enhance the eye’s ability to visually adapt to different light environments, and protect the health of the eye and retina.

Protecting the Smallest Blood Vessels in the Eyes

The health of the eyes depends to a great extent on the integrity of the fine vessels that supply blood to the area. Research shows that Flavay® has the capacity to improve visual performance in various ways.

Flavay® actually strengthens collagen in vascular walls and capillaries (the smallest vessels), making the vessels stronger and more elastic. Flavay® alters the membrane receptor conformation of vascular walls, reducing the damaging effects of the destructive enzymes elastase, collagenase and hyaluronidase, by preventing them from attaching to and degrading vascular walls. Flavay® further prevents destruction of vascular walls by preventing the attachment to membranes of histamine and hyaluronidase, both of which can decrease the strength of vessel walls. Thus, in addition to preventing the root causes of vessel occlusion, Flavay® strengthens vessels, thereby reducing the risk of a rupture or hemorrhage, and helping to prevent and relieve vascular fragility.

Flavay® has been shown to reduce pressure in ophthalmic membranes by preventing abnormal leakage of fluids into the orbital cavity and tissues.

In clinical trials of patients with various types of retinal diseases, including macular degeneration, diabetic retinopathy, retinitis pigmentosa, and hemorrhagic and hypertensive retinopathy, all persons given Flavay® showed significant improvement following therapy. Flavay® has been shown to reduce pressure in ophthalmic membranes by preventing abnormal leakage of fluids into the orbital cavity and tissues.

Diabetic Retinopathy

Retinopathy is especially a problem for diabetics, who suffer from greatly increased capillary permeability in their eyes. The vascular wall and eye lens of a diabetic are especially aggravated due to the nature of the disease.

Diabetic retinopathy is one of the leading causes of blindness and any agent that can help to stem the effects of retinopathy is of value.

There are basically two types of diabetic retinopathy, the background type and the proliferative type. The background type is characterized by microaneurisms (small sacs which develop as a result of excessive vascular dilation), intraretinal hemorrhages, yellowish waxy exudates, and swelling of the macula. The proliferative type is characterized by the development of new vessels in the retina and disk, proliferation of fibrous tissue, vitreous hemorrhage and detachment of the retina. In either case, diabetic retinopathy is one of the leading causes of blindness, and any agent that can help to stem the effects of retinopathy is of value.

Many clinical studies conducted in Europe show that Flavay® greatly improved symptoms in patients with diabetic retinopathies and maculopathies.

Many clinical studies conducted in Europe show that Flavay® greatly improved symptoms in patients with diabetic retinopathies and maculopathies. In one study of 26 diabetic ophthalmic patients, 100 to 200 mg per day of Flavay® proved of therapeutic value in controlling vascular incidents, which are characteristic of diabetic retinopathy. Several weeks of treatment resulted in noteworthy improvement in vascular incidents, with reduced microaneurisms and diminished exudations, and overall improvement in capillary fragility. The vision of those taking Flavay® not only stopped decreasing, but even improved. Flavay® protected cells against free radical damage, and it sealed the microbleedings in the retina that obscure vision.

Clinical studies have conclusively demonstrated Flavay’s® ability to stabilize microcapillaries in the retinal membranes and it has therefore been licensed in France for treating diabetic retinopathy. This shows that Flavay® should be part of the daily nutritional regimen of every diabetic person.

Improving Visual Performance in the Dark After Glare

Double-blind studies have demonstrated that Flavay® may significantly improve visual performance in the dark after glare. In one study of 100 workers who sit in front of computer monitors or drive for a living, the administration of 200mg per day of Flavay® enhanced visual adaptation from bright light. This is the ability of the eyes to see well in a low-light situation after being adjusted to bright light. In the eyes, a substance known as rhodopsin, or visual purple, affects visual acuity in low light. Rhodopsin is made by vitamin A and Flavay appears to enhance the speed of rhodopsin activity, making it easier to go from high to low light. Thus, just as Flavay® enhances the activity of vitamin C in the body, it enhances an important function of vitamin A.

"[A] method for preventing and fighting the harmful biological effects of free radicals in the organism of warm blooded animals and more especially human beings, namely cerebral involution, hypoxia following atherosclerosis, cardiac or cerebral infarction, tumour promotion, inflammation, ischaemia, alterations of the synovial liquid, collagen degradation, among others. The method consists in administering to said animals and especially to human beings an amount, efficient against said effects, of a plant extract with a proanthocyanidins content which has a radical scavenger effect"—U.S. Patent No. 4,698,360 (1987).

Flavay® is the product—used in the actual experiments—by which Dr. Jack Masquelier patented the "Radical Scavenger Effect." of Flavay®

The powerful free radical scavenging protection of Flavay® is especially beneficial to the eyes, with its delicate microcapillaries.

Free Radicals, Cataracts and Macular Degeneration

In the presence of oxygen, ultraviolet light generates free radicals or precursors, and oxidative damage to lens proteins leads to increasing opacity. In the young, repair mechanisms exist, but as we age they become progressively less effective. It has been hypothesized, through both animal and human studies, that oxidation is involved in all types of cataracts and of age-related macular degeneration. A number of epidemiologic studies have found that age-related eye diseases consumed significantly less antioxidants, particularly vitamin C, than did persons who did not develop those eye conditions. Research shows that Flavay® dramatically extends the lifetime of vitamin C in the body, Flavay® provides its own powerful antioxidant protection to the eyes and its tiny blood vessels, and Flavay® enhances the protective effect of alpha-tocopherol (vitamin E) in the eye and retina.

Proven Safety of Flavay®

After more than 60 years of human use, no adverse effects have been observed. Furthermore, intensive biological, toxicological, pharmacological and analytical research was conducted for the purpose of registering it as a medicine in France and other countries in Europe. In one study, daily doses of up to 35,000 mg for six months were determined to cause no adverse effects. Flavay® was also clinically tested, in particular for all sorts of symptoms related to venolymphatic insufficiencies (strenghthening veins, improving circulation and reducing edema and inflammations). The spin-off is a goldmine of data: The rigorous testing to meet the standards required by the health ministries of France, Germany and other European countries demonstrate that Flavay® is highly bioavailable, nontoxic, nonallergenic, noncarcinogenic, nonmutagenic, will not cause birth defects, and is completely safe.

Dr. Masquelier’s unequaled manufacturing process has been conducted for half a century at the very same facilities in France, and under the control of French Pharmaceutical inspection. These time-proven standards serve as a reliable assurance of the quality, consistency, bioavailability and safety of Flavay®.

Who can take Flavay®?

Everyone, from the very young to elderly. Flavay® has no known contraindications (conditions under which it should not be used). Flavay® is completely safe and nontoxic. In fact, clinical trials have been conducted in which pregnant women (troubled by varicose veins and other circulatory problems in the legs) safely used Flavay®.

Why Trust Flavay®

Consumers need to know that the marketplace is full of imitations, various “extracts” and derivative forms of Dr. Masquelier’s scientifically proven and pefected complex. Unfortunately, many have even used Dr. Masquelier’s name and research in unauthorized ways to promote illegitimate products.

Flavay® is the name you can trust for the precisely defined active polyphenol complex proven and perfected by the inventor, Dr. Jack Masquelier, validated by the French Ministry of Health and documented by a library of research consisting of many patents and hundreds of scientific papers, articles, doctorate theses, lectures and presentations. For quality, consistency, bioavailability and safety, consumers may rely upon Flavay®.

Best Protection for the Health of Your Eyes and Retinas

Now available in the United States, Flavay® is the actual product that has been licensed and sold in France for protection against diabetic retinopathy. As discussed above, Flavay® can protect the eyes from free radical damage, support overall circulatory function, reinforce collagen structures of the retina, enhance the eye’s ability to visually adapt to different light environments, and protect the health of the eye and retina.

CLICK HERE TO SEE WHAT FLAVAY® CUSTOMERS ARE SAYING

Buy Flavay Now

Flavay Brochure

To receive more information, use the form below.

We'll personally answer your questions below, or pick up the phone and call us at 1-800-200-1203.

Select:  
 
First Name:  
Last Name:  
Mailing Address:  
more Address space:  
City:  
State/Province:  
Zip:  
Country:  
Phone Number:  
Email*:  

*Sample Email address: name@domain.com

Space is here provided for any questions you may have...

To prevent spam please enter the numbers shown below:

FLAVAY
for a healthy mind & body

Healthy Source

Call: 1-800-200-1203 or 210-481-0067 or Click for Email

Copyright © 1995-2015 Healthy Source, LLC. All rights reserved.

* Statements made herein have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
NOTE: We do not compensate for our endorsements and testimonials. We do not consider paid testimonials to be nearly as valuable as comments from customers who were not compensated and yet liked the products so much they gave their testimonials anyway.
REFERENCES: Top
Masquelier, J. A lifetime devoted to OPC and [pyc]. Alfa Omega Editrice, Pub., 1996. Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega Editrice, Publishers, 1995. Kilham, C., Masquelier, J. OPC: The miracle antioxidant. Keats Publishing, Inc., 1997. Packer, L.,, et al. Antioxidant food supplements in human health. Academic Press, 1999. Mindell, E., et al. Earl Mindell’s vitamin bible for the 21st century. Warner Books, Inc., 1999. Passwater, R.A. The antioxidants: the nutrients that guard your body. Keats Publishing, Inc., 1985. Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants. Keats Publishing, Inc., 1995. Facino RM, et al. Free radical scavenging action and anti-enzyme activities of procyanidines from Vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung, 44: 592-601, 1994. Kuttan R, et al. Collagen treated with catechin becomes resistant to the action of mammalian collagenase. Experientia, 37: 221-223, 1981. Masquelier, J., et al. Stabilization du collagene par les oligomeres procyanidoliques. Acta Therapeutica, 7:101-105, 1981. Masquelier, J. Aspects pharmacologiques nouveaux de certains flavonoides. A Vie Medical 12:1969. Laparra, J., et al. Etude pharmaco-cinetique des oligomers procyandoliques totaux du raisin. Acta Therapeutica, 4, 1978. Laparra, J., et al. Etude pharmacocinetique des oligomeres flavonoliques. Plantes med et phyto, Tome XI, pp. 133-142, 1977. Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de l’action des oligomeres procyanidoliques sur des cellules mesenchymateuses en culture. Ii l’attachment des fibres elastiques aux cellules. (Study of the effect of procyanidolic oligomers on mesenchymal cells in culture. Ii attachment of elastic fibers to the cells.) Pat Biol, (30)6:601-7, 1990. Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular and crystal structure of (+)-2,3-trans-3,4-trans-leucocyanidin [(2r,3s,+r)-(+)-3,3’, 4.4’, 5.7’-Hexahydroxyflavan] dihydrate, and comparison of its heterocyclic ring conformation in solution and the solid state. Journal of the Chemical Society; Perkin Transactions I 1985. pp. 1413-17. Masquelier, J. Proanthocyanidins et radicaux libres. 1985. Uchida, S., et al. Condensed tannins scavenge active oxygen free radicals. Med Sci Res, (15) 1987. pp. 831-832. Ariga, T. Radical scavenging action and its mode in procyanidins b-1 and b-3 from azuki beans to peroxyl radicals. Agric Biol Chem, 54(10) 1990. pp. 2499-2504. Da Silva, R., et. al. Radical scavenger capacity of different procyanidins from grape seeds. Presented at a symposium, “Free radicals in biotechnology and medicine.” Royal Society Of Chemistry, London January 1990, pp. 79-80. Bauman, J., Wurm, G., Bruchhausen, F. “Hemmung der prostagladinsynthetase durch flavonoide und phenolderivate im vergleich nit deren 02 radikalfangereigenschaften” Arch Pharm, (Weinheim) 313 (1980) pp. 330-337. Flesch M., et al., Effects of red and white wine on endothelium-dependent vasorelaxation of rat aorta and human coronary arteries. Am J Physiol 1998;275:1183-94. Fitzpatrick, D.F., Fleming R.C., Bing B, Maggi DA, O'Malley RM. Isolation and characterization of endothelium-dependent vasorelaxing compounds from grape seeds. J Agr & Food Chem In press. Fitzpatrick, D.F., Maggi D, Bing B, Coffey RG. Vasorelaxation, endothelium, and wine. BioFactors 1997;6:455-459. Fitzpatrick, D.F., Hirschfield SL, Ricci T, Jantzen P, Coffey RG. Endothelium-dependent vasorelaxation caused by various plant extracts. J Cardiovasc Pharmacol 1995;26:90-95. Fitzpatrick, D.F., Hirschfield SL, Coffey RG. Endothelium-dependent vasorelaxing activity of wine and other grape products. Amer J Physiol 1993;265:H774-H778. Facino, R.M., et al. Free radical scavenging action and anti-enzyme activities of procyanidines from vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung, 44: 592-601, 1994. Kuttan, R., Donnelly, P.V., Di Ferrante, N. Collagen treated with catechin becomes resistant to the action of mammalian collagenase. Experientia, 37: 221-223, 1981. Masquelier, J. Procyanidolic oligomers. J Parums Cosm Arom, 95: 89-97, 1990. Tixier, J.M., et al. Evidence by in vivo and in vitro studies that binding of [pyc] to elastin affects its rate of degradation by elastases. Biochem Pharmacol, 33: 3933-3939, 1984. Kakegawa, H., et al. Chem. Pharm. Bull. 33:5079, 1985. Harmand, M.F., Blanquet, P. The fate of total flavanolic oligomers extracted from ‘vitus vinifera l.’ in the rat. European Journal of Drug Metabolism and Pharmaccokinetics. 1978, No. 1 pp. 15-30. Delrieu, P., Ding J., Escande, B., Samain, D. Free-radical scavenging activity of proanthocyanidolic oligomers encapsulated in glycospheres: an in vivo and in vitro study. Cosmetology Department & S Biovectors, Ramonville St. Agne France. pp. 1-9. Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i converting enzyme by flavanolic compounds: in vitro and in vivo studies. Planta Medica, May 26, 1986. pp. 12-15. Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques chez l’animal-oedenme de la patte. Sanofi Res Toul Cedex Fr, pp31-40. Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques chez l’animal-activite aniagoniste vis-a-vis des mediateurs de l’inflamation. Sanofi Res Toul Cedex Fr, pp. 31-40. Dubos, C., Durst, G., Hugonot, H. Evolution de la resistance capillaire, spontanement ou artificiellement diminuee par l’action d’une substance capillaro-toxique chez des personnes agees--action benefique d’un agnet actif sur la micro-circulation: l’Endotelon. Inform. Therapeut. 1980. pp. 302-305. Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude d’un microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7, 1990. Lagrue, G., Olivier-Martin, F., Grillot, A. “Etude des effets des oligomeres du procyanidol sur las resistance capillaire dand l’hypertension arterielle et certaines nephropathies.” Sen. Hosp. Paris 18-25 Septembre, 1981. Beylot, C., Bioulac, P. Essai therapeutique d’un angioprotecteur peripherique, l’Endotelon. Actualite Therapeutique Gaz. Med. de France (87)22:2919-24, 1980. Lesbre, F.X., Tigaud, J.D. Effect de l’Endotelon sur l’indice de fragilite capillaire dan une population specifique: les sujets cirrhotiques. Gaz. Med. de France, (90)24 1983. Sarrat, L. Abord therapeutique des troubles fonctionnels des membres inferieurs par un microangioprotecteur l’Endotelon. Bordeaux Med, 11:685-8, 1981. Delacroix, P. Etude en double aveugle de l’Endotelon dans l’insuffisance veineuse chronique. Therapeutique, la Revue de Medicine, (27-28) Sept. 1981. pp. 1793-1802. Thebaut, J.F, Thebaut, P., Vin, F. Etude de l’Endotelon dand les manifestations fonctionnelles de l’insuffisance veineuse peripherique-resultats d’une etude en double aveugle portant sur 92 patients.” Gazette Medicale, (92)1, 1985. pp. 96-100. Chang, W.C., Hsu, F.L. Inhibition of platelet aggregation and arachidonate metabolism in platelets by procyanidins. Prostagland Leukotri Essent Fatty Acids, 38:181-8, 1989. Masquelier, J. [pyc]: recent advances in the therapeutical activity of procyanidins. Supplement of Planta Medica, Journal of Medicinal Plant Research and Journal of Natural Products, July 1980 pp. 243-256. Henning, B., et al. Lipid peroxidation and endothelial cell injury: implications in atherosclerosis. Free Rad Path & Med, (4)1988 pp. 99-106. Masquelier, J. “Les procyanidols du vin leur role dans l’alcoolisme.” pp. 88-93. Gazave, J.M. “Notions recentes sur les capillaires” unpub. bulletin from the Laboratoire De Physiologie Patholigie pp. 26-29. Ruf, J.C. Wine and polyphenols related to platelet aggregation and atherothrombosis. Office International Vigne et du Vin, Nutrition and Health Unit, Paris France; Drugs under Experimental and Clinical Research (Switz.) 25/2-3 (125-131), 1999. Blaszo, G. Gabor, M. Oedema-inhibiting effect of procyanidin. Acta Physiologica Academiae Scientiarum Hungaricae, Tomus 56(2):235-240, 1980. Tayau, M.F, LeFevre, G. Action du leucocyanidol sur l’hyalaluronidase. Bull Soc Pharm Bordeaux, 95:132-136, 1956. Lamy, M. Utilization des oligomeres procyanidoliques en gynecologie. Essai Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22. Henriet, J.P “Une Etude Exemplaire Pour Un Phlebotrope: l’etude EIVE.’ Unpub., pp. 77-83. Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation des oligomeres procyanidoliques dans la paroi des capillaires sanguins du poumon decobaye. Acta Therapeutica (8) 1982. pp. 223-237. Kuttan, R., Donnelly, P., Di Ferrante, N. “Collagen treated with (+) -catechin becomes resistant to the action of mammalian collagenase.” Laboratory of Connective Tissue Research, Dept. of Biochem. Baylor Col. of Med., Houston TX. 28, May, 1980. Gendre, P., Laparra, J., Barraud, E. “Effect protecteur des oligomeres procyanidoliques sur le lathyrisme experimental chez le rat.” Ann. Pharm. Francaises, (43)1, 1985 pp. 61-73. Corbe, C., Boissin, J.P., Siou, A. Light vision and chorioretinal circulation. Study of the effect of procyanidolic oligomer (Endotelon). Jn. Fr. Opthalmol, (11)5:453-460, 1988. Boissin, J.P., Corbe C., Siou, A. Chorioretinal circulation and dazzling: use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol Fr, 88(2):173-4, 177-9, 1988. Proto, F. et al. Electrophysical study of vitis vinifera procyanoside oligomers effects on retinal function in myopic subjects. Ann Ott Clin Ocul, 114:85-93, 1988. Saracco, J.B., Estachy, G.M. Etude d l’Endotelon en opthalmologie. Gaz Med de France, 88:2035-2038, 1981. Scharrer, A., Ober, M. Anthocyanosides in the treatment of retinopathies. Klin Monatsbl Augenheilkd, 178:386-389, 1981. Corbe, C., et al. Microangiopathy of the retina. J. Fr. Opthalmol, 11:453, 1988. Verin, M.M., Vildy, A., Maurin, J.F., Retinopathies et O.P.C. Bordeaux Medicale, (16)11. pp. 1467-74, 1978. Soyeux, A. et al. Endotelon. Diabetic retinopathy and hemorheology. Bull Soc Ophtalmol Fr. 87(12):1441-4, 1987. Fromantin, M. “Les oligomeres procyanidoliques dans le traitement de la fragilite capillaire et de la retinopathie chez les diabetiques. A propos de 26 cas.” Med Int, 16(11):432-434, Nov. 1981. Arne, J.L. Contribution a l’etude des oligomeres procyanidoliques: Endotelon, dans la retinopathie diabetique (a propos de 30 observations). Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982. Baruch, J. Effect of Endotelon in postoperative edema. Results of a double-blind study versus placebo in 32 female patients. Ann Chir Plast Esthet 29(4):393-5, 1984. Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism in rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62, 1981. Gabor, M. Pharmacologic effects of flavonoids on blood vessels. Angiologica, 9:355-374, 1972. Havsteen, B. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol, 32:1141-48, 1983. Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer, H.J. Berkhauser Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger., 1977. Masquelier, J. Action protectrice du vin sur l’ulcere gastrique. Resultats, p. 61. Amella, M., et al. Inhibition of mast cell histamine release by flavonoids and bioflavonoids. Planta Medica, 5116-20, 1985. Packer, L., et al. The antioxidant miracle: your complete plan. John Wiley & Sons, Inc., 1999. Shaw, R. How [Australian] [pyc] [MASQUELIER’s®] Helps Sports People. Masquelier, J. Procyanidolic oligomers (leucocyanidins). Parfums Cosmet Arom 95:89-97, 1990. Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques (Endotelon) dans le traitement des lymphoedemes post-therepeutiques de members superieurs. Symposium Satellite, Congres International d’Angiologie, Toulouse, France, 4-7 Oct. 1989. Laparra, J., Michaud, J. Masquelier, J. Action des oligomeres procyanidoliques sur le cobaye carence en vitamin c. Tavaux Originaux, University of Bordeaux, 1976. Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’oxydation de l’acide ascorbique par les ions cuivriques. Bull. de la Societe de Chimie Biologique XXXIII (3-4) 1951. pp. 302-304. Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’acide ascorbique-oxydase. Bull. de la Societe de Chimie Biologique XXXIII (3,4) 1951. pp.304-306 Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T., Nonaka, G., Mishioka, I. “Inhibitory effects of tannins on hyaluronidase activation and on the degranulation from rat mesentery mast cells.” Chem. Pharm. Bull. 33(11)1985. 5079-5082. Reiman, H.J., Lorenz, M., Fischer, R., Frolich, H., Meyer, J. “Histamine and acute haemorrhagic lesions in rat gastric mucosa: prevention of stress ulcer formulation by (+)-catechin, an inhibitor of specific histidine decarboxylase in vitro.” Dirkhauser Verlag,Vol. 7/1, 1977. Pariente, J.J. Parientl-Amsellem, J. “Les oedemes post-traumatoqies chez le sportif: essai controle de l’Endothelon.” Actualite Therapeutique 90(3) 2/11 1983 pp. 231-235. Masquelier, J., et al. “Flavonoids et [pyc]” Int J Vit Nut Res, (49)3:307-311, 1979. Yu, C. L. et al. Mutagenicity of proanthocyanidins. Food Chem. Toxicol. 25(2):135-9, 1987. Pantaleoni, G.C., Quaglino, D. Univerisity of Aquila Pharmacol-Toxicologica Report, 1971. Laparra, J., et al., Acta Therapeutica, 4:233, 1978. Volkner, Wolfgang Muller, Ewald, Micronucleus assay in bone marrow cells of the mouse with [pyc]. Cytotest Cell Research GmbH & Co., projects 143010 & 143021; Feb. 1989. Acute and chronic toxicity tests. International Bio-Research, Inc., Hanover, Germany, 1967-1971. Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin content in vegetable extracts to be used in the preparation of medicines. Bull. Soc. Pharm. Bordeaux, 129:51-65, 1990.
Top
Contact Us | BUY NOW